Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease
NCT06118515Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of letermovir in congenital cytomegalovirus infection (cCMV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Plasma letermovir area under the curve at Day 14. Started Feb 2025; status: completed.
02
Drugs
letermovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT06118515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118515.